Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Total Liabilities (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Total Liabilities for 3 consecutive years, with $55.2 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Total Liabilities rose 189.04% year-over-year to $55.2 million, compared with a TTM value of $55.2 million through Sep 2021, up 189.04%, and an annual FY2020 reading of $21.9 million, up 349.11% over the prior year.
  • Total Liabilities was $55.2 million for Q3 2021 at Black Diamond Therapeutics, up from $36.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $55.2 million in Q3 2021 and bottomed at $4.9 million in Q4 2019.
  • Average Total Liabilities over 3 years is $25.0 million, with a median of $21.9 million recorded in 2020.
  • The sharpest move saw Total Liabilities crashed 79.84% in 2020, then skyrocketed 482.8% in 2021.
  • Year by year, Total Liabilities stood at $4.9 million in 2019, then surged by 349.11% to $21.9 million in 2020, then surged by 151.82% to $55.2 million in 2021.
  • Business Quant data shows Total Liabilities for BDTX at $55.2 million in Q3 2021, $36.9 million in Q2 2021, and $32.5 million in Q1 2021.